Penicillin and vancomycin induce a lytic response in Streptococcus pneumoniae that requires the N-acetylmuramyl-L-alanine amidase LytA. We show that clinical isolates of pneumococci of capsular serotypes 1, 4, 6B, and 23F were generally less lytic to penicillin than pneumococci of serotypes 14 and 3. In addition, most 9V isolates were less lytic to vancomycin, compared with isolates of other serotypes. Parent-mutant pairs expressing and not expressing capsular serotypes 2, 4, and 9V were compared for antibiotic-induced lysis. The nonencapsulated variants were considerably more lytic after b-lactam and/or vancomycin treatment, and antibiotic tolerance was seen only in the context of capsule expression. Conversion from a nonlytic to a lytic phenotype, after loss of capsule expression, required an intact lytA autolysin gene. Exogenous addition of purified LytA gave a lower lytic response in capsulated strains, compared with that in nonencapsulated mutants. Spontaneous autolysis in stationary phase also was negatively affected by capsule expression in an autolysindependent manner. Long-term starvation in the stationary phase of the vancomycin-and penicillin-tolerant isolate I95 yielded nonencapsulated mutants that had lost antibiotic tolerance and were lytic to penicillin and vancomycin. The 9V capsular locus of I95 and one of these stationary phase-selected mutants were completely sequenced. The only difference found was a 1-bp frameshift deletion in the cps9vE gene of the lytic mutant, encoding a uridine diphosphate-glucosyl-1-phosphate transferase. Two additional independently isolated lytic mutants of I95 from the stationary phase also contained mutations in the same region of cps9vE, which identified it as a mutational hot spot. This report demonstrates that capsular polysaccharides negatively influence the lytic process and contribute to antibiotic tolerance in clinical isolates of pneumococci.
Penicillin and vancomycin induce a lytic response in Streptococcus pneumoniae that requires the N-acetylmuramyl-L-alanine amidase LytA. We show that clinical isolates of pneumococci of capsular serotypes 1, 4, 6B, and 23F were generally less lytic to penicillin than pneumococci of serotypes 14 and 3. In addition, most 9V isolates were less lytic to vancomycin, compared with isolates of other serotypes. Parent-mutant pairs expressing and not expressing capsular serotypes 2, 4, and 9V were compared for antibiotic-induced lysis. The nonencapsulated variants were considerably more lytic after b-lactam and/or vancomycin treatment, and antibiotic tolerance was seen only in the context of capsule expression. Conversion from a nonlytic to a lytic phenotype, after loss of capsule expression, required an intact lytA autolysin gene. Exogenous addition of purified LytA gave a lower lytic response in capsulated strains, compared with that in nonencapsulated mutants. Spontaneous autolysis in stationary phase also was negatively affected by capsule expression in an autolysindependent manner. Long-term starvation in the stationary phase of the vancomycin-and penicillin-tolerant isolate I95 yielded nonencapsulated mutants that had lost antibiotic tolerance and were lytic to penicillin and vancomycin. The 9V capsular locus of I95 and one of these stationary phase-selected mutants were completely sequenced. The only difference found was a 1-bp frameshift deletion in the cps9vE gene of the lytic mutant, encoding a uridine diphosphate-glucosyl-1-phosphate transferase. Two additional independently isolated lytic mutants of I95 from the stationary phase also contained mutations in the same region of cps9vE, which identified it as a mutational hot spot. This report demonstrates that capsular polysaccharides negatively influence the lytic process and contribute to antibiotic tolerance in clinical isolates of pneumococci.
Streptococcus pneumoniae is a major community-acquired pathogen that causes both localized and systemic invasive disease. One characteristic feature of pneumococci is their tendency to undergo autolysis after reaching the stationary phase and after exposure to antibiotics. Three murein hydrolases are known to par- zyme is enzymatically less active during logarithmic growth or the peptidoglycan is not accessible as a substrate during active growth. LytA-containing extracts from actively growing pneumococci are capable of causing lysis when added exogenously to cells only in the stationary phase or in the presence of antibiotic, which indicates that there is a requirement for triggering activity, even when the substrate is accessible [6] . Whatever the mechanism, autolysis is clearly a strictly regulated process. It has been demonstrated that lytic antibiotics, such as penicillin and vancomycin, do not directly kill target bacteria, such as S. pneumoniae, but trigger a signal transduction process that leads to an activation of an endogenous death process, including activation of autolysis [7] [8] [9] . Part of the antibiotic-induced death response in pneumococci involves lysis mediated by the activation of LytA. Hence, a lytA mutant of S. pneumoniae R6 is not lysed by either penicillin or vancomycin and is not killed to the same extent by these lytic antibiotics as is the R6 wild type-that is, it exhibits antibiotic tolerance [10, 11] .
The above studies have indicated some components of the lytic machinery and its activation cascade, but evidence also suggests that lysis is modulated by processes not part of the structural lytic machinery. For instance, S. pneumoniae is known to undergo spontaneous phase variation readily visualized by transitions between opaque and transparent colony forms. The opaque variants appear less lytic and less transformable and produce more capsular polysaccharide and less teichoic acid and lipoteichoic acid than the transparent forms [12] . The mechanisms behind the reduced lytic behavior for opaque variants is not known, although they have been reported to produce slightly lower levels of LytA. Also, the level of branched muropeptides in the pneumococcal peptidoglycan has been shown to affect antibioticinduced lysis, as well as autolysis, which suggests that structural modifications of the target for LytA will have consequences for lytic behavior [13, 14] .
In a recent study of antibiotic tolerance among clinical isolates of pneumococci, isolates that belonged to certain capsular serotypes were frequently less lytic and therefore tolerant to penicillin and/or vancomycin than were isolates belonging to other serotypes [11] . Here, we ask whether this apparent correlation among antibiotic-induced lysis, antibiotic tolerance, and serotype can be directly linked to an effect of capsular polysaccharides on the lytic process.
MATERIALS AND METHODS

Collection of pneumococcal strains.
Strains I95, T4lytA, T4lytB, T4lytC, T4, T4R, T4RlytA, T4RlytB, T4RlytC, D39, R6, and Lyt4-4 are described in table 1. I95 is a penicillin-and vancomycin-tolerant clinical isolate of type 9V recovered from blood [11] . R6 and the autolysin-defective R6 transformant mutant derivative Lyt4-4 [15] were obtained from the Rockefeller University Collection (New York, NY). D39 is a type 2 strain obtained from Peter Hermans (Rotterdam, The Netherlands). Bacteria were grown in semisynthetic medium [16] supplemented with 0.1% yeast extract (hereafter "c+y medium"; Difco). One hundred thirty-four clinical nasopharyngeal and invasive isolates belonging to types 1, 3, 4, 6B, 9V, and 23F (table 2), which were selected to be as epidemiologically different (isolates from different geographic areas and different time points) as possible, were used to study lysis rates. Construction of nonencapsulated type 4 mutant T4R. The organization of the capsule locus of the sequenced strain type 4 is very similar to that published for serotype 19F [17, 18] . Thus, disruption of the first open-reading frame (ORF), cps19fA, by insertional duplication, results in complete loss of capsule, which is most likely due to polarity effects on downstream genes. An internal polymerase chain reaction (PCR) fragment (534-900 bp) of ORF cps19fA was amplified by use of the primers SAUCPSA1 (5 -TAG TGA GAT CGA AAA TGT TAC GCA AC-3 ) and SAUCPSA2 (5 -GAC ACC GAT CTA ATA GGA CCA TAG GTG TC-3 ). Both primers have a sequence tag comprising a Sau3AI restriction site (underlined). The 366-bp large fragment was digested with Sau3AI and was cloned into the Sau3AI-digested vector pWG5. Transformation of the smooth serotype 4 strain selecting for chloramphenicol resistance led to a rough (nonencapsulated) mutant of the type 4 strain. The correct insertion was confirmed by Southern blot analysis. Loss of the capsule was determined by a negative quellung reaction.
Construction of nonencapsulated type 9V mutant I95csp9vA. Genomic DNA was prepared from the 9V clinical isolate I95, and PCR analysis was performed to produce a fragment containing part of the cps9vA gene. The primers used were 9VEco (5 -ATG GAA TTC GAC TGG GAC TGA TAA TGA A-3 ) and 9VBam (5 -TGA CTG GAT CCA CCA TCT GCG ATT GGT-3 ), containing an EcoRI site and a BamHI site, respectively (underlined). This PCR product (406-830 bp of cps9vA) was cloned into the pJDC9 vector using the EcoRI and BamHI restriction sites. After transformation of I95 with this construct, nonencapsulated mutants were selected for on blood plates containing erythromycin. The correct insertion was confirmed by Southern blot analysis. A negative quellung reaction and a negative quantitative ELISA confirmed loss of capsular expression.
DNA transformation. The recipient pneumococcal strain was grown to an OD 260 of 0.1 and then put on ice. Chromosomal DNA from the donor strain and competence-stimulating peptide were incubated with the recipient strains at 30ЊC for 30 min and then at 37ЊC for 2 h. The culture was plated on blood agar plates containing either erythromycin or chloramphenicol. Serotyping. Pneumococcal strains were identified by optochin sensitivity. Strains were serotyped at the Swedish Institute for Infectious Disease Control by gel diffusion, using 46 type-or group-specific sera [19] that were obtained from the World Health Organization (WHO) Collaborating Center for Reference and Research on Pneumococci at Statens Seruminstitut (Copenhagen). Isolates that could not be typed or found to belong to a group that included 11 type were examined by gel diffusion and/or the capsular reaction test (Quellung test) with type-specific antisera [20, 21] from the WHO Collaborating Center.
Drug susceptibility testing. All isolates were tested for drug susceptibility, as described elsewhere [22] . In brief, an agar dilution method was used with serial 2-fold dilutions of each antibiotic incorporated in PDM II Sensitivity Test Agar (Biodisk) supplemented with 5% horse blood. The MIC was defined as the lowest concentration of an antibiotic that did not permit visible growth. The following antibiotics were used: benzyl penicillin (Astra) and vancomycin (Eli Lilly).
Lysis rate. When cultures reached an OD 620 of 0.25-0.3, penicillin or vancomycin was added at a concentration of 10 times the MIC (penicillin, 0.1-20 mg/L; vancomycin, 5-10 mg/ L). Turbidity (measured in a Sequoia-Turner spectrophotometer; absorbance 620 nm) was monitored hourly for 4-5 h after addition of the antibiotic, which is a time that has been shown to clearly differentiate tolerant and nontolerant strains [23] . Viability counts were performed by diluting samples from each culture in PBS and by plating on blood agar plates. In cases in which the mutants carried resistance markers (chloramphenicol or erythromycin), the assays always were performed in the absence of selectable antibiotics, to avoid secondary effects mediated by those antibiotics, as shown for erythromycin by Robertson et al. [24] . The presence of the selectable marker was instead checked after each experiment by restreaking colonies on selective media. Spontaneous autolysis was performed with and without the addition of erythromycin, and the difference found between encapsulated and nonencapsulated strains was not caused by the addition of erythromycin [24] . All strains were tested for LytA-dependent lysis by adding 2% sodium deoxycholate to a bacterial suspension in independent experiments.
Quantitative ELISA. Samples for ELISA were prepared by growing bacteria to mid-log phase, washing them, and resuspending them in PBS, followed by sonication for s. Total 5 ϫ 10 protein was determined for both supernatants and sonicated cells by use of the Bio-Rad Protein Assay, and all samples were stored at Ϫ20ЊC. Type-specific rabbit antiserum was coated at a 1:2000 dilution in 0.05 mol Na 2 CO 3 (pH 9.6) overnight at room temperature onto microtiter plates. Each subsequent step was performed at room temperature and was preceded by washing 3 times with 0.05% Tween 20 in PBS. Dilutions of double samples of both supernatants and sonicated cells were added to the plates and were incubated for 2 h with shaking. As standard, purified capsular polysaccharide of type 9V (ATCC) was used. A type 9V-specific mouse monoclonal antibody (HASP14; Statens Seruminstitut) was added at a 1:2000 concentration and incubated for 1.5 h with shaking. HRP-conjugated rabbit-a-mouse antibody (P0260; DAKO) was used as a secondary antibody (diluted 1:2000 and incubated for 1 h). Detection was performed by the addition of o-phenylendiamine (Sigma) in citric acid buffer containing 0.04% H 2 O 2 . The reaction was stopped after 5-10 min by adding 1 mol of HCl, and absorbance at 490 nm was determined.
Northern blot hybridization. Total RNA of S. pneumoniae was prepared by extraction with hot phenol, according to a modification of the method of Janzon et al. [25] . Bacteria grown in c+y medium to an OD of 0.4 were harvested by centrifugation and were washed with TES buffer (50 mmol Tris HCl [pH 7.5], 5 mmol EDTA, and 50 mmol NaCl) containing chloramphenicol (0.2 mg/mL). The pelleted bacteria were dissolved in TES buffer supplemented with NaAc (50 mmol [pH 4.5]) and SDS (1%) and were incubated at 65ЊC for 3 min. The lysates were extracted twice with unbuffered phenol at 65ЊC and once with phenol/chloroform (pH 7.5) at room temperature. RNA was precipitated with ethanol and was treated with RQ1-DNase (Promega). Concentration of RNA was determined spectrophotometrically at 260 nm. Samples containing 5 mg of total RNA were analyzed by Northern blotting, as described elsewhere [25] . An internal fragment of the lytA gene (nt 689-1535; GenBank accession no. M13812) was amplified by PCR, radiolabeled with [aϪ 32 ]-P-dCTP (Amersham) by use of a random prime labeling kit (Roche Molecular Biochemicals), and was used as probe. Radioactivity was detected by a radioisotope imaging system (Phosphorimager 455SI; Molecular Dynamics).
Western blot hybridization. For lysate preparation, culture was grown in c+y medium to an OD 620 of 0.5 at 37ЊC in CO 2 . Five milliliters of the culture was pelleted. The pellet was resuspended in 200 mL of 1ϫ Laemmli's loading buffer, boiled for 5 min, cooled, and sonicated for s on ice. Lysate 2 ϫ 15 was centrifuged to remove debris, and the supernatant was quantified by use of RCDC Protein Assay (Bio-Rad). One microgram of lysate was boiled for 5 min, separated by SDS-PAGE, and transferred to a polyvinylidene fluoride membrane. After blocking with PBS/0.05% Tween 20/5% nonfat milk for 5 min at room temperature, the membrane was incubated with primary anti-LytA (1:2000; Covance) overnight at 4ЊC. After rinsing with PBS/0.05% Tween 20, the membrane was incubated with a horseradish peroxidase-conjugated secondary antibody (1:10,000; Bio-Rad) for 30 min at room temperature and was developed by use of the SuperSignal West Pico Chemiluminescent Substrate (Pierce).
LytA purification. The LytA produced recombinantly was made by a plasmid given by Lopez [26] . The purification was done according to the method of Sanchez-Pulleys et al. [27, 28] (a reagent called BugBuster from Novagen was used instead of sonication). The purified LytA was titrated using Lyt4-4 and a penicillin concentration 10 times the MIC to find the minimal amount necessary to cause a decrease in optical density. Protein concentration was determined by use of RCDC reagents (BioRad), and purity was determined by gel electrophoresis.
Sequencing of the 9V csp gene cluster. Constant regions surround all known pneumococcal capsular gene clusters: dexB upstream of the locus and aliA downstream of the locus. On the basis of these constant regions, 2 PCR primers were designed, CAP1 (5 -CTT GCG GCC AAT CAG GTT CAG-3 ) and CAP2 (5 -GAA CTG TTG AAC CTG TCC TGG C-3 ). PCR was performed by use of the Expand long template system (Roche), according to manufacturers instructions, with genomic DNA from the 9V clinical isolate I95 as a template. This produced a 25-kb PCR fragment that was sequenced using CAP1 and CAP2. New primers then were designed from the obtained sequences, and so on, until the full sequence was known. The sequence of the capsular region of the nonencapsulated mutant I95R1 was generated by use of primers from the determined wild-type sequence.
RESULTS
Degree of antibiotic-induced lysis correlates with capsular serotype. The degree of lysis, after treatment with penicillin or vancomycin at a concentration 10 times the MIC, was tested for 134 pneumococcal isolates belonging to serotypes 1, 3, 4, 6B, 9V, 14, and 23F (figure 1). These isolates were either nasopharyngeal or blood isolates taken from different geographic locations at different times to increase the likelihood of genetic diversity among strains belonging to the same capsular serotype. Although there were variations within each serotype, isolates belonging to serotype 14, in general, were highly lytic after treatment with penicillin and vancomycin, as was the case for isolates belonging to serotype 3. Isolates of serotypes 1, 4, 6B, and 23F were less lytic to penicillin but fully lytic to vancomycin, whereas most serotype 9V isolates were less lytic to vancomycin but were more lytic to penicillin, compared with isolates of serotypes 1, 4, and 23F. The average lytic ability against penicillin and vancomycin for each of these serotypes is given in table 2. Thus, although the average type 4 isolate only exhibited 7% lysis after penicillin treatment, the average type 14 isolate, under the same experimental conditions, showed 65% lysis. The average lysis for different serotypes varied less for vancomycin than for penicillin and was the lowest for serotype 9V (57%) and the highest for serotype 14 (91%) (table 2).
To address whether variation in lytic behavior among clinical isolates belonging to the same serotype could be explained by differences in amount of capsule produced, a quantitative ELISA was performed, with the caveat that this method would not be sensitive enough to identify small differences in capsular expression. We chose serotype 9V strains, because we have reported previously on one 9V isolate that exhibited tolerance to both penicillin and vancomycin, isolate I95 [8, 11] . Bacterial supernatants and pellets from 4 clinical isolates, including I95, of varying lytic capability were analyzed, but no significant correlation between lytic capacity and amount of 9V capsule could be observed. Two nonencapsulated strains of I95 origin (I95R1 and I95cps9vA) also were included as negative controls (data not shown).
Antibiotic-induced and spontaneous autolysis in encapsulated pneumococcal strains versus their nonencapsulated mutant derivatives. To examine more directly a potential role for capsule expression in the lytic behavior of pneumococci, we compared a number of mutant pairs expressing or not expressing capsular polysaccharide. Most studies on autolysis and tolerance to lytic antibiotics have been carried out in the nonencapsulated spontaneous mutant R6. Strain D39 is the type 2 encapsulated ancestral strain of R6. Interestingly, strain D39 was much less lytic after treatment with penicillin and also slightly less lytic after treatment with vancomycin, compared with R6 ( figure 2A and 2B ). In fact, D39 and the lytA mutant derivative of R6, Lyt4-4, responded in a similar way to penicillin, whereas D39 was more extensively lysed with vancomycin than was Lyt4-4. Strain D39 exhibited not only a decreased penicillin-induced lysis but also decreased spontaneous autolysis, monitored after 20 h of incubation, compared with R6 (data not shown).
A chloramphenicol resistance cassette was introduced by insertional duplication into the csp4A gene of the capsular locus of strain T4, giving the nonencapsulated strain T4R. Both strains were equally sensitive to deoxycholate, which suggests normal expression of active LytA amidase. Interestingly, there was only a slight penicillin-induced lysis after 4 h in the encapsulated strain T4, versus almost complete lysis for T4R (figure 2C) . The increased lysis of T4R to penicillin was dependent on LytA, because the lytA mutant T4RlytA was nonlytic ( figure  2C ). Vancomycin-induced lysis also was less for T4, compared with T4R, but the difference was smaller than for penicillininduced lysis ( figure 2D ). The lytA-knockout mutation in encapsulated T4 significantly reduced the lytic response after vancomycin treatment, compared with wild-type T4, showing that LytA-mediated lysis can be activated in T4 by vancomycin. In contrast, T4 and T4lytA showed essentially the same low lytic response to penicillin. Thus, expression of the type 4 capsule seems to interfere with penicillin-induced lysis but less with vancomycin-induced lysis. Expression of the type 4 capsule also had a significant effect on spontaneous autolysis, in that lysis was delayed for several hours in T4, compared with T4R ( figure  3 ). After 25 h of incubation, lysis also was apparent in T4 but not in T4lytA. Therefore, the expression of the type 4 capsule appears to interfere, in a LytA-dependent manner, with penicillin-induced lysis, as well as with stationary phase-induced lysis, but less with vancomycin-induced lysis.
Pneumococci have been shown to express 2 murein hydrolases in addition to LytA. Knockout mutant derivatives of strain T4R, in either lytB or lytC, behaved essentially as T4R and were more lytic to both penicillin and vancomycin (figure 2C and 2D), compared with T4RlytA. Also, the antibiotic-induced lytic response in lytB and lytC mutant derivatives of capsulated T4 was similar to that in parental T4. These data suggest that neither LytB nor LytC contributes significantly to antibioticinduced lysis in the pneumococcus. However, spontaneous autolysis was affected by inactivation of lytB or lytC in capsulated T4. Hence, T4lytB and T4lytC showed a delayed lytic response, compared with T4. The nonencapsulated T4R, T4RlytB, and T4RlytC showed a faster autolytic response than T4RlytA and any of the corresponding capsulated derivatives. Although T4R and T4RlytB behaved similarly, spontaneous autolysis was de- layed for ∼6 h in T4RlytC (figure 3). The differences in antibiotic-induced lysis noted among the different T4 variants could not be explained by opaque/transparent-phase transitions, because both the tested T4 and T4R strains formed predominantly transparent colonies (data not shown).
Prolonged stationary-phase conditions have been shown to result in nonencapsulated mutants of serotype 3 isolates [29] . Similar nonencapsulated spontaneous mutants also were obtained from the antibiotic tolerant 9V strain I95. After 19 days of incubation, small-colony variants emerged, and the numbers of viable bacteria increased in the culture. A number of these small-colony variants were tested for 9V capsule production. They were all nonencapsulated, were sensitive to deoxycholate, and showed the same pulsed-field gel electrophoresis profile as I95 (data not shown). One of these variants, I95R1, was tested further and showed a considerably higher degree of vancomycin-and penicillin-induced lysis ( figure 2E and 2F) . Also, spontaneous autolysis was initiated much earlier in nonencapsulated I95R1 than in 9V capsulated I95 ( figure 3) . The longterm starvation experiment was repeated, and, after incubation at 37ЊC for 12 days, new nonencapsulated mutants of I95 were recovered.
To identify the mutation in I95R1 responsible for the conversion to a fully lytic nontolerant phenotype, the entire 17368-bp large serotype 9V capsular locus was sequenced in I95 and I95R1 (figure 4). Only 1 mutation at position 1007 of gene csp9vE was found. In the mutant, a G residue was deleted, which led to a Ϫ1 frameshift mutation in the cps9vE gene encoding a UDP-glucosyl-1-phosphate transferase essential for serotype 9V capsule biosynthesis [30] . Also, 4 nonencapsulated mutants of I95 from the second experiment were subjected to sequencing of the cps9vE gene, and all showed different mutations in the cps9vE gene, compared with I95R1 (figure 4). Three mutants had the same mutation where a C was substituted, with a T at position 1003, creating a stop codon. These mutants probably represent siblings of 1 mutant, I95R2, because they were obtained in the same experiment. The fourth mutant, I95R3, had a Ϫ1 frameshift mutation at position 976, which led to a frameshift mutation different from that found in I95R1. I95R2 and I95R3 exhibited the same high lytic response as I95R1 to penicillin and vancomycin (data not shown), which suggests that the identified spontaneous mutations in csp9vE in each mutant are responsible for the high lytic response after antibiotic treatment.
To further verify the role of capsular 9V expression in antibiotic-induced lysis, an erythromycin resistance cassette was used to inactivate the cps9vA gene (the first gene in the 9V capsular operon) of the penicillin-and vancomycin-tolerant The entire 9V capsular region was sequenced from I95, as well as I95R1. The sequence only differed by one 1-bp deletion in the cpsE gene of the mutant. The 9V capsular region of I95 was identical in sequence to that recently reported for another 9V strain [30] . In mutants I95R2 and I95R3, only the cpsE genes were sequenced. Strain 961793 is a spontaneous nonencapsulated mutant, as described by van Selm et al. [30] .
9V isolate I95. The resulting I95cps9vA mutant was lacking detectable production of serotype 9V capsule, as measured by quantitative ELISA and the quellung reaction. Of significance, I95cps9vA showed a considerably higher degree of vancomycinand penicillin-induced lysis (figure 2E and 2F), compared with encapsulated I95, and did not significantly differ from the spontaneous cps9vE mutants.
Strains T4 and I95 were not only less lytic, compared with their nonencapsulated mutants after antibiotic treatment, but also exhibited a considerably lower degree of killing after 4 h of penicillin or vancomycin treatment. Thus, for T4R, the degree of penicillin-and vancomycin-induced killing was 2 log higher than that for T4 after 4 h (data not shown). For I95csp9vA, penicillin-induced killing was only ∼1 log higher than that for I95 (data not shown). However, vancomycininduced killing was at least 2 log higher in this nonencapsulated mutant, compared with that in the wild type. Thus, the reported vancomycin tolerance of I95 [11] clearly depends on capsular 9V expression.
Mechanism of the negative effect of capsule on lysis. To more clearly delineate the relationship between capsule and LytA activity, 3 types of experiments were performed. First, the mechanism of changes in lytic response in the presence and absence of capsule did not appear to be due to changes in transcription of the lytA gene. Northern blot analysis did not show any differences in the expression of lytA-specific mRNA between R6 and D39, T4 and T4R, and I95 and I95csp9vA (figure 5A). Second, the amount of LytA in various strains was determined by Western blot analysis to ensure that capture of LytA to the surface was not impeded by capsule ( figure 5B ). In all strains tested, an equally intense band corresponding to LytA could readily be visualized by Western blot, except for the insertional duplication mutant T4lytA. Lyt4-4 apparently produced an enzymatically inactive form of LytA. Third, the ability of purified LytA, when added exogenously, to lyse encapsulated and nonencapsulated pneumococci was tested. When purified LytA was added to either T4 or T4R at an OD of 0.2, no lysis was recorded until the population reached an OD of 1.0, when exogenously added LytA significantly increased the rate of lysis, compared with spontaneous autolysis. Exogenously added LytA had a significantly greater effect on T4R lysis than on T4 lysis (figure 6).
DISCUSSION
Lysis associated with both penicillin and vancomycin treatment in the pneumococcus requires the expression of the major autolysin LytA. This enzyme also needs to be present for pneumococci to undergo spontaneous autolysis after reaching the stationary phase and plays a role in cell separation during active Figure 5 . Expression of the LytA amidase is not affected by capsular expression. A, Northern blot of total RNA prepared from pneumococci expressing or not expressing capsular polysaccharides. An internal lytA fragment was used as a probe. Note that the autolysis-negative mutant Lyt4-4 is expressing lytA transcript, whereas T4lytA is not. B, Western blot of total cell extracts from pneumococci expressing or not expressing capsular polysaccharides. Note that Lyt4-4 is expressing a nonenzymatically active form of LytA, whereas T4lytA expresses no LytA. There were no significant differences in the expression of lytA mRNA or LytA protein, depending on capsule expression. Furthermore, absence of either LytB or LytC had no effect on LytA expression. Figure 6 . Lytic response of exogenously added LytA amidase. Addition of purified LytA amidase evoked a lytic response in nonencapsulated T4R but not in the encapsulated parental strain T4, which suggests that type 4 capsule expression prevents LytA from reaching its substrate. Note the delayed lytic response for T4R, which suggests that peptidoglycan in actively growing pneumococci, and in the absence of antibiotics, is not sensitive to LytA action.
growth. What has remained a mystery is the mechanism that exerts negative control on LytA-mediated lysis during normal growth and how this negative control can be relieved during antibiotic-induced lysis and after reaching stationary phase.
In the present article, we demonstrate a dramatic difference in lytic behavior depending on capsular expression and capsular serotype. Thus, at least for 4 different pairs, D39/R6 (expressing/not expressing type 2 capsule), T4/T4R (expressing/not expressing type 4 capsule), and I95/I95R1 plus I95/I95csp9vA (expressing/not expressing type 9V capsule), antibiotic-induced lysis was considerably higher in the nonencapsulated variants. Because a lytA mutation in both an encapsulated and nonencapsulated background abolished antibiotic-induced lysis, we argue that the effect of capsule expression must act through LytA. However, the amount of LytA was not the determining factor, since both Northern blot and Western blot analyses of LytA expression revealed no correlation between expression of LytA and the lytic ability of the microbe strains. In contrast to the requirement for LytA, absence of the other 2 hydrolases, LytB and LytC, had no detectable effect on antibiotic-induced lysis, regardless of whether the organism was encapsulated.
Encapsulation had a significant effect on spontaneous stationary phase-induced lysis, which also was dependent on LytA. Surprisingly, inactivation of either lytB or lytC delayed spontaneous autolysis in capsulated T4, and at least LytC had an effect on spontaneous autolysis of nonencapsulated T4R.
Our results suggest that neither the amount nor the extracellular availability of endogenously synthesized LytA explains the difference between lysis of capsulated and nonencapsulated pneumococcal strains. Because enzymatically active LytA, added exogenously, also is negatively affected by the expression of capsule, the underlying differences in lytic behavior between capsulated and nonencapsulated strains cannot be explained by different control mechanisms that might be operative before export of the endogenously synthesized LytA autolysin.
We could readily isolate nonencapsulated mutants from an aging culture of strain I95 expressing a serotype 9V capsule, which suggests that the loss of capsule provides pneumococci with a selective growth advantage under long-term stationaryphase conditions. The underlying mechanism for the selection of capsule loss is not clear, particularly in view of our findings that capsule expression delay spontaneous autolysis. Strain I95 is a penicillin-nonsusceptible clinical isolate that expresses both vancomycin and penicillin tolerance. This isolate is part of a clonal complex, in which all tested isolates show a reduced lysis after vancomycin or penicillin treatment. We have no explanation why I95 shows an even lower ability to lyse than do members of the same clonal complex [11] . We used a quantitative ELISA to determine whether the former isolate produced higher levels of the 9V capsule than did other isolates of type 9V but found no evidence for this (data not shown). The nonDownloaded from https://academic.oup.com/jid/article-abstract/189/2/328/893127 by guest on 31 March 2019 encapsulated in vitro-generated mutant I95csp9vA, as well as the in vivo-selected I95R1 csp9vE mutant, both became fully lytic after vancomycin and penicillin treatment and showed a similar degree of killing as nontolerant strains. Although complementation experiments have yet to be performed to fully link the in vivo-selected csp9vE mutation to the mutant phenotype, the finding that independent mutations in this gene all resulted in a loss of antibiotic tolerance adds strength to our suggestion that expression of the 9V capsule is required for the tolerant phenotype of strain I95.
Mutant I95R1 contained a Ϫ1 frameshift deletion of a G residue at position 1007 within the csp9vE gene. Interestingly, spontaneous nonencapsulated mutants were described recently for another 9V isolate [30] . One such mutant was sequenced and also found to have a Ϫ1 frameshift deletion of a G residue in csp9vE, but at position 977. Both mutants, with deletions at position 977 and 1007, would code for a truncated polypeptide ending at the same stop codon. Also, 2 other nonencapsulated mutants of I95, obtained after long-term stationary-phase conditions, I95R2 and I95R3, showed other mutations in the csp9vE gene. These 4 mutations have been generated within a region of 30 bp. This region contains short repeats of A and G residues that might enhance replication slippage, resulting in the three Ϫ1 frameshift mutations. Therefore, we believe that the 30-bp region in csp9vE represents a mutational hot spot. It will be interesting to determine whether nonencapsulated csp9vE mutants also appear in the nasopharynx of carriers.
The hypothesis that capsular polysaccharide itself may negatively influence LytA-mediated antibiotic-induced lysis was supported by our finding that the lytic behavior differed among different serotypes. Thus, most type 3 and type 14 isolates were highly lytic, whereas type 1, 4, 6B, and 23F isolates were less lytic to penicillin but virtually fully lytic to vancomycin. Only serotype 9V showed less lytic ability to both penicillin and vancomycin. Certain capsular polysaccharides, such as types 2, 4, 6A, 6B, 7F, 8, 14, 19F, and 23F, have been shown to be associated with peptidoglycan. The nature of this interaction is not known but has been suggested to be covalent [31] . Interestingly, the type 3 capsule was not found to be cell wall associated.
One may envision several alternative mechanisms by which a capsular polysaccharide (particularly, if it is covalently attached to the cell wall) may contribute to resistance to autolysis. The capsular polysaccharide may interfere with the primary hydrolytic activity of LytA. Autolytic phenomena involve the activity of LytA localized outside the plasma membrane in the cell-wall space [32, 33] , and a capsular polysaccharide may block or slow down the translocation of LytA to the cell-wall space, which creates a deficit of the enzyme in the cell wall. A capsular polysaccharide may change the chemical environment in the vicinity of the covalent bonds that are the targets of LytA protein, such that enzyme activity is suppressed. It also is possible that the capsular polysaccharide sterically blocks access of the enzyme either to the covalent bonds that are its substrate in the peptidoglycan or to the choline residues in the cell-wall teichoic acid, which are essential ligands with which LytA must interact during its hydrolytic attack [34] [35] [36] . It also is possible that the effect of the capsular polysaccharide is indirect, because, through its particular chemistry, the capsule polysaccharide may add stability (mechanical and/or physicochemical) to the plasma membrane, protecting it from rupture, which must precede the "lysis" of the bacterial cells measured by the decrease in the optical density of a culture.
